Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.34 and traded as high as $1.42. Cortexyme shares last traded at $1.33, with a volume of 77,816 shares traded.
Cortexyme Trading Down 5.0 %
The company has a market cap of $40.10 million, a price-to-earnings ratio of -0.45 and a beta of 1.40. The company has a fifty day moving average price of $1.65 and a two-hundred day moving average price of $1.34.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Axon: Long-Term Outlook Is Strong Despite Federal Budget Worries
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Stocks Powering the Future of Autonomous Driving
- Trading Halts Explained
- These 3 Stocks Are Generating Massive Returns on Capital
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
